Closely held PharmaJet announced the publication of a study in the top-tier journal Vaccine, which demonstrates the benefits of the company’s Tropis needle-free system compared to needle and syringe (N/S) for...
Search results for - PharmaJet
PharmaJet to present insights from DNA cancer vaccine partner trials at WVC 2025
Closely held PharmaJet announced it will present insights from several DNA cancer vaccine partner trials using PharmaJet’s Precision Delivery Systems at the World Vaccine Congress (WVC) on April 23, 2025 at 12:25 pm ET...
PharmaJet spotlights Nature publication on Stratis IM System benefits
Closely held PharmaJet has announced that the peer-reviewed journal Nature has published findings from a U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) Phase 1 trial, demonstrating that the...
PharmaJet and Scancell forge alliance to develop and commercialize needle-free DNA vaccine for advanced melanoma
Closely-held PharmaJet has announced a strategic partnership with Scancell Holdings (AIM:SCLP) to supply its Stratis Intramuscular (IM) Needle-free Injection System for delivery of Scancell’s advanced melanoma DNA...
PharmaJet’s innovative needle-free system chosen for WHO polio immunization campaign in Somalia
Closely-held PharmaJet announced that its Tropis Intradermal (ID) Needle-free System was selected by WHO for use in a house-to-house immunization campaign targeting more than 170,000 children, age four to 59 months, in...
PharmaJet creates two SABs
Closely-held PharmaJet created two scientific advisory boards (SABs) – infectious diseases and oncology – comprised of leading pharmaceutical industry experts in immunology, cancer, research, and policy shaping...
PharmaJet launches Phase 1 trial of Precision Delivery Systems-delivered VEE vaccine
PharmaJet launched a Phase 1 clinical study evaluating a Venezuelan Equine Encephalitis (VEE) DNA vaccine delivered via the company’s needle-free Precision Delivery Systems. The Phase 1 trial, sponsored by PharmaJet and...
PharmaJet launches Nigerian study of Tropis-administered poliovirus vaccine
PharmaJet launched a study in Nigeria to evaluate the intradermal administration of a fractional inactivated poliovirus vaccine (fIPV) using the company’s Tropis ID Needle-free Injection System. Children at 22 urban and...
PharmaJet partner, Scancell, posts positive data from Phase 2 advanced melanoma trial
PharmaJet partner, Scancell, reported positive data from the first phase of a Phase 2 clinical trial evaluating PharmaJet’s needle-free vaccine delivery system for treatment of advanced melanoma. The Phase 2 study’s...
Former Pfizer vaccine president Nanette Cocero joins PharmaJet board
PharmaJet appointed Nanette Cocero, Ph.D., a recognized leader in the global pharmaceutical industry with broad commercial and business experience coupled with an extensive clinical and scientific background, to the...
